VENTURE CAPITAL POST

Swiss pharmaceutical giant Roche has experienced an improved revenue this year. However, it also saw a decline in market cap as its invetors remain cautious on broader industry factors.

Quadria Capital, a healthcare focused private equity firm, is in the process of closing out deals in four companies in Southeast Asia. Its investments are mostly on pharmaceutical and healthcare corporations.

The Therapeutic Goods Administration (TGA) of Australia seeks suggestions after it announced its plan to adopt new EMA guidelines. Said guidelines include clinical development of drugs against Duchenne Muscular Dystrophy (DMD). TGA will accept comments until 9 November.

The U.S. Securities and Exchange Commission's top enforcement chief warned on Tuesday that too many pharmaceutical companies are failing to accurately portray their dealings with federal drug regulators - a problem that could get them in trouble.

The Canadian government will require pharmaceutical companies to post public notices when drugs are not available or face fines, Health Minister Rona Ambrose said on Tuesday.

Security researchers say they have uncovered a cyber espionage ring focused on stealing corporate secrets for the purpose of gaming the stock market, in an operation that has compromised sensitive data about dozens of publicly held companies.

There is no trace of Shenzhen Lanhao Days Electronic Technology Co Ltd at its listed address in the beige and pink-tiled "Fragrant Villa" apartment complex in this southern Chinese city. The building's managers say they’ve never heard of it.

Fujifilm Holdings Corp said on Tuesday that it expects its influenza drug Avigan to become a highly effective drug to treat Ebola.

Japan's Fujifilm Holdings Corp said it was difficult to estimate the profitability of its influenza drug Avigan, which has been earmarked to fight Ebola, given the uncertainty over the spread of virus, a company executive said on Thursday.

A Chinese drugmaker with close military ties is seeking fast-track approval for a drug that it says can cure Ebola, as China joins the race to help treat a deadly outbreak of a disease that has spread from Africa to the United States and Europe.

BioFire is bought out by BioMerieux for USD450 million, funded through debt.

Conactus Pharmaceutical raised US $66 million after the company offered 6,000,000 shares at US $11 each during the initial public offering.